News Sentiment

SRPT sentiment intelligence

Sarepta Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.95 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.7% over one week, +23.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Trading Systems Reacting to (SRPT) Volatility

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend inactive 23.8% over four weeks
Fair value -75.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 43
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 8
simplywall.st 6
Sarepta Therapeutics 4
Simply Wall Street 3
DirectorsTalk Interviews 3
Stocktwits 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 23
Analyst action 10
Regulatory and legal 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 70
Business Wire Direct company coverage

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. granted equity awards to 30 new employees in the second quarter of 2026 as a material inducement for their employment. These awards, totaling 151,305 restricted stock units (RSUs), were approved by the Compensation Committee and are in accordance with N

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 06:39
Source
Business Wire
NeurologyLive Direct company coverage

FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy

The FDA has accepted Sarepta Therapeutics' supplemental new drug applications (sNDAs) for casimersen (Amondys 45) and golodirsen (Vyondys 53) for Duchenne muscular dystrophy (DMD), setting a PDUFA target action date of February 28, 2027. These submissions aim to convert the exist

Tone
Positive 62/100
Event
Analyst action
Published
01 Jul 2026 03:39
Source
NeurologyLive
Sarepta Therapeutics Direct company coverage

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

Sarepta Therapeutics announced that the FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45® and VYONDYS 53® for Duchenne muscular dystrophy (DMD), with a PDUFA target action date of February 28, 2027. These sNDAs aim to convert the accelerated approvals of

Tone
Positive 71/100
Event
Analyst action
Published
30 Jun 2026 18:39
Source
Sarepta Therapeutics
Benzinga Direct company coverage

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

Sarepta Therapeutics is advancing towards full FDA approval for its Duchenne Muscular Dystrophy drugs, VYONDYS 53 and AMONDYS 45. The FDA has accepted supplemental New Drug Applications, setting a target action date of February 28, 2027. This move is supported by data from the Ph

Tone
Positive 82/100
Event
Analyst action
Published
30 Jun 2026 17:11
Source
Benzinga
Intellectia AI Direct company coverage

FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments

The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of these Duchenne muscular dystrophy (DMD) treatments. The applications are supported by clinical and real-world data showing positive

Tone
Positive 65/100
Event
Analyst action
Published
30 Jun 2026 17:11
Source
Intellectia AI
Investing.com Direct company coverage

FDA accepts Sarepta filings for two Duchenne therapies

Sarepta Therapeutics Inc. announced that the FDA has accepted its supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy treatments, for review. The FDA has set a target action date of February 28, 2027, to convert their accelerated approval

Tone
Positive 67/100
Event
Analyst action
Published
30 Jun 2026 13:39
Source
Investing.com